
Sanjiv Shah
Articles
-
Jan 6, 2025 |
digitalcommons.library.tmc.edu | Ambarish Pandey |Sanjiv Shah |Javed Butler |Dean Kellogg
KeywordsAging, Animals, Exercise Tolerance, Heart Failure, Diastolic, HumansAbstractExercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals.
-
Nov 27, 2024 |
radcliffecardiology.com | Sanjiv Shah |Ashley Park |Andrew Coats |Nazli Okumus
Video Published: Views: 22 Likes: 0 Average (ratings) AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).
-
Oct 28, 2024 |
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
-
Oct 22, 2024 |
jacc.org | Scott Solomon |John W. Ostrominski |Xiaowen Wang |Sanjiv Shah
Introduction Abnormalities of cardiac structure and function are common in heart failure (HF) and remain powerful predictors of HF onset and progression.1-4 Increasing evidence indicates that obesity is a major driver of both adverse cardiac remodeling and HF, particularly heart failure with preserved ejection fraction (HFpEF).5-10 Indeed, obesity-related HFpEF is now recognized as a widely prevalent and high-risk phenotype within the broader HFpEF spectrum,11,12 characterized by...
-
Oct 1, 2024 |
radcliffecardiology.com | Sanjiv Shah |Erin D. Michos |Alison Bailey |Tina Ticinovic Kurir
Video Published: Views: 2 Likes: 0 Average (ratings) HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892). EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →